IHAM
MDGL icon

Integral Health Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Integral Health Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$14.5M – 83
2022
Q4 		$14.5M Buy
+50,000
New +$4.89M 3.05% 10

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Health Asset Management's MDGL Position: Q1 2026 in Review

Integral Health Asset Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 25,000 shares worth $13.1M. The stake represents 0.63% of the portfolio and ranks #42 among its holdings.

378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Integral Health Asset Management held 25,000 shares of Madrigal Pharmaceuticals worth $13.1M as of Q1 2026.
  • Madrigal Pharmaceuticals was a new Integral Health Asset Management position in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.63% of Integral Health Asset Management's portfolio in Q1 2026, its #42 holding.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.